Apheresis Market to Inflate with Substantial 10.2% CAGR Over the Review Period (2017-2023): MRFR
The apheresis market is getting significant traction due to the growing emphasis on the specific features of blood that impacts researches and transfusion. It is a technology that purifies blood or separate components for a smoother after-study related to blood. It relies on centrifugation and membrane filtration technology. From the donor’s body, the apheresis machine can draw in blood and filter the required components based on the molecular size and weight. It has specific functions related to diseases such as neurological, cardiovascular, renal, autoimmune, hematological and others.
The global apheresis market is expected to clock an impressive 10.2% CAGR during the forecast period (2017-2023), reveals Market Research Future (MRFR). The report encompasses segmental analysis and factors that can trigger market growth in the coming years. Among the major factors, growth in the number of registered cases regarding cancer has become impactful. In addition, blood transfusion plays an important role in several difficult surgical procedures which can provide traction to the market. Healthcare-related researches can also open up growth possibilities.
On the flip side, the apheresis market can be restrained by the high-cost associated with it. At the same time, lack of skilled individuals is also impacting the market substantially by taking a dig at the CAGR during the forecast period.
The global apheresis market can be segmented by product, procedure, methods, application, and end-users.
Based on the product, the apheresis market includes devices and disposables. The devices segment can be sub-segmented into platelets separators, plasma separators, and others.
Procedure-wise, the apheresis market comprises leukapheresis, plateletpheresis, plasmapheresis, erythrocytapheresis, and others.
Method-based segmentation of the apheresis market includes filtration and centrifugation. Centrifugation consists intermittent flow centrifugation, continuous flow centrifugation, and others.
Application-wise, the apheresis market can be segmented into oncological diseases, immunological diseases, hematological diseases, cardiovascular diseases, renal diseases, neurological diseases, and others.
Based on end-users, the apheresis market includes hospitals, blood banks, and others.
Geographical analysis of the apheresis market includes the Americas, Europe, Asia Pacific (APAC), and Rest-of-the-World (RoW).
Technological superiority, robust infrastructure, consumer-friendly healthcare insurance policy, and other factors are proving vital for the North America market growth. The market is further getting tractions from the research and development sector here the laboratories are promoting requirement for the system. At the same time, investments made by private and public sectors are chalking out good times for the market ahead.
Europe assumes the second lead with similar features like that of the Americas to support the apheresis industry. It gets further help from ever-vigilant governments who take serious steps to advance the healthcare sector. This squarely impacts the apheresis market growth as well.
The APAC region is expected to emerge as the fastest growing region during the forecast period. Several emerging economies are providing substantial backings to the healthcare sector to become a lucrative opportunity for the developed countries. Medical tourism is a factor that can provide thrust to the market.
Significant contributions are getting made to the global apheresis market by Kaneka Corporation (Japan), Terumo BCT Inc. (US), Fresenius Medical Care (Germany), Nikkiso Co. Ltd. (Japan), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), HemaCare Corporation (US), Cerus Corporation (US), Haemonetics Corporation (US), Kawasumi Laboratories Inc. (Japan), Therakos, Inc. (U.S.), and others.
In January 2018, MedAware Systems launched a database, backed by its SOHInfo division. The database includes cohort studies, clinical trials, medical journals, and others. MedAware Systems has launched the database with an aim to increase awareness regarding apheresis and provide all-round support.
In July 2018, the U.S. FDA approved sodium citrate 4% w/v anticoagulant solution USP procedure during an automated apheresis procedure, a unique method initiated by Terumo BCT. Terumo BCT, a global leader in therapeutic apheresis, blood component, and cellular technologies, focused on the solution for mainly the shortage of sodium citrate that is impacting patients.